Eli Lilly and Company (LLY)
Is Eli Lilly Going To $1,100?
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.
Eli Lilly launches Alzheimer's drug Donanemab in India
U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India.
Eli Lilly Price Prediction: This Is Where The Stock Will End This Year
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY | LLY Price Prediction).
Lilly Bounces Into ‘Sell in May' Territory as Pricing Pressures Loom
The market adage “Sell in May and Go Away” rarely fits a single name cleanly.
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Eli Lilly remains a 'strong buy' as I see robust revenue growth across obesity, diabetes, immunology, and oncology franchises. LLY's MOUNJARO and ZEPBOUND delivered Q1 2026 revenues of $8.66B [+125%] and $4.16B [+80%] respectively, driving a 56% YoY total revenue increase. Pipeline momentum is strong: FOUNDAYO launched, Retatrutide and Eloralintide advanced, and EBGLYSS/JAYPIRCA show double-digit growth with label expansion catalysts ahead.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.
Signal: Eli Lilly Stock Remains a "Buy" After Earnings
Eli Lilly And Co (NYSE:LLY) has capitalized on last week's impressive first-quarter earnings report.
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Eli Lilly said on Wednesday it would commit an additional $4.5 billion investment across two of its three sites in Indiana, bringing the company's total capital expansion commitments in the state since 2020 to more than $21 billion.
Our Strongest Conviction Call: Eli Lilly Headed 21% Higher in 12 Months
Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak.
